Skip to content

Trial · Interventional

CompletedPhase 1/2Registry data

The Influence of Oxytocin on Socio-communicative Sensitivity

Overview

Status
Completed
Phase
Phase 1/2
Enrollment
31 participants (actual)
Sponsor
KU Leuven · Other
Design
Randomized · Quadruple masking
Countries
1 country

Belgium

Start
21 Nov 2016
Primary completion
30 May 2017
Completion
30 Jul 2017
First posted
30 Mar 2017
Last update posted
22 Jul 2022
Conditions
Oxytocin

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
201620172018
  1. Ph 1/2

    The Influence of Oxytocin on Socio-communicative Sensitivity

    NCT03096249

    21 Nov 2016 to 30 Jul 2017

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Oxytocin (OT) is a neuropeptide that acts as a neurotransmitter and neuromodulator in the brain. Previous studies have shown that intranasal administration of OT improves social cognition and behavior (e.g. emotion recognition). In the current study, we want to gain more insight into the underlying mechanisms by which OT influences emotion recognition. More specifically, we will investigate whether intranasal administration of OT enhances the salience of social (compared to non-social) information and whether it increases the neural sensitivity for subtle socio-emotional cues, by recording scalp electroencephalography (EEG) during Fast Periodic Visual Stimulation (FPVS).

Interventions

  • OxytocinDrug
  • PlaceboOther

Arms2

  • Experimental

    Oxytocin

    Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716) will be used for intranasal administration of a single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)

  • Placebo comparator

    Placebo

    Physiological water (sodium chloride (NaCl) solution) Administration via nasal spray

Primary outcomes4

Outcomes the sponsor listed as primary.

  1. social salience frequency-tagging FPVS

    Time frame · random: 30-70 minutes after nasal spray

    Registry description

    EEG recording during simultaneous (superimposed) presentation of social stimuli (faces) and non-social stimuli (objects or houses), at a frequency of 6 and 7.5Hz, respectively (counterbalanced).

  2. Oddball face detection FPVS paradigm

    Time frame · random: 30-70 minutes after nasal spray

    Registry description

    EEG recording during presentation of objects (at 6 Hz) and faces (inserted as an "oddball" every fifth image, thus at a frequency of 1.2 Hz)

  3. Oddball identity discrimination FPVS paradigm

    Time frame · random: 30-70 minutes after nasal spray

    Registry description

    EEG recording during presentation of neutral faces of the same person (same identity, presented at 6 Hz) and the face of another person (inserted as an "oddball" every fifth image, thus at a frequency of 1.2 Hz)

  4. Oddball expression generalization FPVS paradigm

    Time frame · random: 30-70 minutes after nasal spray

    Registry description

    EEG recording during presentation of neutral faces with different identities (at 6 Hz) and faces with an emotional expression (fear, anger, happy; inserted as an "oddball" every fifth image, thus at a frequency of 1.2 Hz)

Secondary outcomes(6)
  1. Emotion recognition: accuracy on the Palermo Matching task (65 items)

    Time frame · 80 minutes after nasal spray (after all EEG measures)

    Registry description

    Three faces are shown on the screen. Two of them display the same emotion and the participant has to indicate which face shows a different emotion

  2. resting state EEG

    Time frame · 45-50 minutes after nasal spray (after two FPVS paradigms)

    Registry description

    EEG recording, while presenting a fixation cross

  3. Social responsiveness: Social Responsiveness Scale (SRS)

    Time frame · Baseline

    Registry description

    Self-report version of the SRS. In addition to a Total score reflecting severity of social deficits in the autism spectrum, the SRS generates scores for five Treatment subscales: Social Awareness, Social Cognition, Social Communication, Social Motivation, and Restricted Interests and Repetitive Behavior.

  4. Social phobia: Social Phobia Inventory (SPIN)

    Time frame · Baseline

    Registry description

    A 17-item questionnaire that screens for, and measures, the severity of social anxiety disorder.

  5. Attachment: State Adult Attachment Measure (SAAM)

    Time frame · Baseline

    Registry description

    The SAAM measures 3 different aspects of adult attachment: Security, Anxiety, Avoidance. There are 21 Likert-style questions with a score between 1 and 7 (7 for each of the three subscales).

  6. Mood: Positive And Negative Affect Schedule (PANAS)

    Time frame · 90 minutes after nasal spray

    Registry description

    The Positive and Negative Affect Schedule (PANAS) comprises two mood scales, one that measures positive affect and the other which measures negative affect. It consists of 20 items (10 for each subscale).

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2024

4 results

Social functioning predicts individual changes in EEG microstates following intranasal oxytocin administration: A double-blind, cross-over randomized clinical trial.

Tomescu et al. 2024Psychophysiologycited by 6

PMID 38594888DOI 10.1111/psyp.14581PUB-38594888

Free to read · publisher termsCC BY-NC-ND4 results

Eligibility

Who could join, as posted.

Sex
Male
Age
from 18 Years up to 30 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * age between 18 and 30 years * male * right-handed * typically developing * Normal or adjusted-to-normal vision (with glasses or lenses) Exclusion Criteria: * psychiatric disorder * neurological disorder (e.g. epilepsy, migraine) * color blindness * psychoactive medication

PepBank is a research reference. Talk to a doctor before you use any peptide.